

Election of the chair of the Meeting (item 2)

The Nomination Committee of Swedish Orphan Biovitrum AB (publ), which consists of Daniel Nodhäll, chair (Investor AB), David Meek (chair of the Board of Directors), Thomas Ehlin (The Fourth Swedish National Pension Fund (AP4)) and Anders Hansson (AMF – Tjänstepension och Fonder), proposes that attorney-at-law Emil Boström from Mannheimer Swartling Advokatbyrå is elected chair of the Meeting.

Fees for the members of the Board of Directors and the auditor (item 13)

The Nomination Committee proposes the following:¹

- that fees to be paid to the Board of Directors should be SEK 2,175,000 (1,885,000) to the chair of the Board of Directors and SEK 720,000 (625,000) to each of the other members of the Board of Directors elected by the Annual General Meeting, that fees for work in the Audit Committee should be SEK 245,000 (235,000) to the chair and SEK 145,000 (135,000) to each other member of such committee, that fees for work in the Compensation & Benefits Committee should be SEK 155,000 (150,000) to the chair and SEK 105,000 (100,000) to each other member of such committee, that fees for work in the Scientific Committee should be SEK 155,000 (150,000) to the chair and SEK 105,000 (100,000) to each other member of such committee, and that fees for work in the Transaction Committee should be SEK 155,000 (150,000) to the chair and SEK 105,000 (100,000) to each other member of such committee,
- that, in addition to the fees proposed above, for each physical meeting of the Board of Directors held in Sweden, a meeting fee of EUR 2,000 (unchanged) is paid to the members of the Board of Directors that reside in Europe outside the Nordic countries and a meeting fee of USD 5,000 (3,500) is paid to the members of the Board of Directors that reside outside Europe, and
- that the fees to the auditor should be paid in accordance with normal standards and approved invoice.

The number of members of the Board of Directors, deputy directors, auditors and deputy auditors (item 14)

The Nomination Committee proposes the following:

- that eight ordinary members of the Board of Directors without deputies should be appointed, and
- that one auditor without any deputy auditor should be appointed.

Election of the chair, the members of the Board of Directors and the auditor (item 15)

The Nomination Committee proposes the following:

¹ Figures within parenthesis refer to fees for the corresponding period the previous year.

- that Christophe Bourdon, David Meek, Zlatko Rihter, Helena Saxon, Staffan Schüberg, Filippa Stenberg and Anders Ullman should be re-elected as ordinary members of the Board of Directors, that Iris Loew-Friedrich should be elected as new ordinary member of the Board of Directors and that David Meek should be re-elected as chair of the Board of Directors, and
- that Ernst & Young AB should be re-elected as auditor of the company until the end of the Annual General Meeting 2026, in accordance with the Audit Committee's recommendation.

Iris Loew-Friedrich

Iris Loew-Friedrich (born 1960) holds an MD and PhD in internal medicine from Goethe University Frankfurt, Germany.

Iris is chair of the board of Evotec SE and of Celosia Therapeutics Pty Ltd and she is a board member of Fresenius SE & Co. KGaA. She is also a member of the advisory boards of Spave Science Inc., Fondazione Telethon, Pierre Fabre S.A. and Helmholtz Health. Her previous experience includes Executive Vice President, Chief Medical Officer and Head of Development at UCB S.A/Schwarz Pharma AG, Vice President, Head of Global Development at BASF Pharma and various positions in clinical development at Aventis/Hoechst Marion Roussel/Hoechst AG (changed names due to mergers).

The Nomination Committee recommends the elected Board members to build their own holdings of shares in the company

Similar to previous years, the Nomination Committee recommends the Board of Directors of Swedish Orphan Biovitrum AB (publ) to establish a shareholding policy pursuant to which the members of the Board of Directors, who do not already have such holdings, are expected to, over a five year period from joining the Board of Directors, acquire an ownership in Swedish Orphan Biovitrum AB (publ) shares with a market value which is expected to correspond to at least one year board remuneration, before taxes, excluding remuneration for committee work.